Bone Biologics Corp Stock Performance
| BBLG Stock | USD 1.53 0.07 4.38% |
The firm shows a Beta (market volatility) of -1.11, which signifies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Bone Biologics are expected to decrease slowly. On the other hand, during market turmoil, Bone Biologics is expected to outperform it slightly. Bone Biologics Corp has an expected return of -1.07%. Please make sure to confirm Bone Biologics Corp maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Bone Biologics Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bone Biologics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's essential indicators remain nearly stable which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Last Split Factor 1:8 | Dividend Date 2018-07-24 | Last Split Date 2023-12-20 |
1 | Whats Going On With Bone Biologics Corp Stock - MSN | 01/29/2024 |
2 | Investment Report - Stock Traders Daily | 02/16/2024 |
3 | Bone Biologics Reports Progress With NB1 Clinical Program | 03/01/2024 |
4 | Bone Biologics Announces Pricing of 2.0 Million Public Offering | 03/04/2024 |
5 | Bone Biologics Announces Closing of 2.0 Million Public Offering | 03/06/2024 |
6 | Acquisition by Heshmatpour Amir F of 1826779 shares of Bone Biologics subject to Rule 16b-3 | 03/20/2024 |
| Begin Period Cash Flow | 7.5 M |
Bone |
Bone Biologics Relative Risk vs. Return Landscape
If you would invest 363.00 in Bone Biologics Corp on January 25, 2024 and sell it today you would lose (210.00) from holding Bone Biologics Corp or give up 57.85% of portfolio value over 90 days. Bone Biologics Corp is currently does not generate positive expected returns and assumes 7.7739% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Bone, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bone Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bone Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bone Biologics Corp, and traders can use it to determine the average amount a Bone Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1374
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BBLG |
Estimated Market Risk
| 7.77 actual daily | 68 68% of assets are less volatile |
Expected Return
| -1.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bone Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bone Biologics by adding Bone Biologics to a well-diversified portfolio.
Bone Biologics Fundamentals Growth
Bone Stock prices reflect investors' perceptions of the future prospects and financial health of Bone Biologics, and Bone Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bone Stock performance.
| Return On Equity | -2.02 | ||||
| Return On Asset | -0.96 | ||||
| Current Valuation | (2.17 M) | ||||
| Shares Outstanding | 879.18 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.51 X | ||||
| EBITDA | (9.43 M) | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 12.77 M | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 5.44 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | (34.01) X | ||||
| Market Capitalization | 1.35 M | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
About Bone Biologics Performance
To evaluate Bone Biologics Corp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Bone Biologics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Bone Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Bone Biologics Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Bone's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 368.20 | 327.29 | |
| Return On Tangible Assets | (2.39) | (2.51) | |
| Return On Capital Employed | (3.24) | (3.08) | |
| Return On Assets | (2.39) | (2.51) | |
| Return On Equity | (3.08) | (2.93) |
Things to note about Bone Biologics Corp performance evaluation
Checking the ongoing alerts about Bone Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bone Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bone Biologics Corp generated a negative expected return over the last 90 days | |
| Bone Biologics Corp has high historical volatility and very poor performance | |
| Bone Biologics Corp may become a speculative penny stock | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Bone Biologics Corp has a frail financial position based on the latest SEC disclosures |
- Analyzing Bone Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bone Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Bone Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bone Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bone Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bone Biologics' stock. These opinions can provide insight into Bone Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.01) | Return On Assets (0.96) | Return On Equity (2.02) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.